Immunoglobulin Constant Region Fc Receptor Binding Agents.
IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
MX 2,009,013,004 [MORE INFO
STROME SCOTT E [US]; SCHULZE DAN H; BLOCK DAVID S
Type of Offer:
« More Biotech Patents